IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDEXX Laboratories, Inc.

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF (Symbol: GSLC) where we have detected an approximate $164.7 million dollar outflow -- that's a 1.1% decrease week over week (from 113,100,000 to 111,800,000). Among the largest underlying components of GSLC, in trading today Verisign Inc (Symbol: VRSN) is up about 0.3%, Idexx Laboratories, Inc. (Symbol: IDXX) is up about 0.7%, and Fastenal Co. (Symbol: FAST) is up by about 0.2%. For a complete list of holdings, visit the GSLC Holdings page » The chart below shows the one year price performance of GSLC, versus its 200 day moving average:
Looking at the chart above, GSLC's low point in its 52 week range is $94.8763 per share, with $126.96 as the 52 week high point — that compares with a last trade of $126.87. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
CTSO Stock Predictions
ACFN Videos
SDRL shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable ETF Outflow Detected - GSLC, VRSN, IDXX, FAST

Below is Validea's guru fundamental report for IDEXX LABORATORIES INC (IDXX). Of the 22 guru strategies we follow, IDXX rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth.
IDEXX LABORATORIES INC (IDXX) is a large-cap growth stock in the Fish/Livestock industry. The rating using this strategy is 88% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of IDEXX LABORATORIES INC
More Information on Partha Mohanram
About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School.
Additional Research Links
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

IDXX Quantitative Stock Analysis

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.
In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.
However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Our proprietary system currently recommends Idexx Laboratories (IDXX) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.
While there are numerous reasons why the stock of this Animal diagnostic and health care company is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings Growth
Arguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Idexx is 11.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 17.6% this year, crushing the industry average, which calls for EPS growth of 14.8%.
Cash Flow Growth
Cash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.
Right now, year-over-year cash flow growth for Idexx is 6%, which is higher than many of its peers. In fact, the rate compares to the industry average of -2.5%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 14.6% over the past 3-5 years versus the industry average of 6.3%.
Promising Earnings Estimate Revisions
Superiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Idexx have been revising upward. The Zacks Consensus Estimate for the current year has surged 3.3% over the past month.
Bottom Line
Idexx has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination indicates that Idexx is a potential outperformer and a solid choice for growth investors.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 77.2%, outperforming 4.6% growth of the industry during the same time frame. The S&P 500 Composite has increased 14.3%.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Insulet develops, manufactures and markets the Omnipod System — an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of the Omnipod Insulin Management System (Omnipod) and the Omnipod DASH Insulin Management System (Omnipod DASH), a next-generation digital mobile Omnipod platform.
The company reports revenues under three segments — U.S. Omnipod, International Omnipod and Drug Delivery. The Drug Delivery business offers ties with pharmaceutical and biotechnological companies to use a customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time.
Factors Favoring PODD’s Share Price Growth
Insulet’s share price is trending upward, prompted by strategic market expansion efforts. In 2024, Insulet received FDA clearance for type 2 label expansion for Omnipod 5. Since then, Omnipod 5 was launched in France and the Netherlands, and in January 2025, it was introduced in five additional countries — Italy, Denmark, Finland, Norway, and Sweden. It was also launched in Australia in March 2025.
Additionally, the strong performance of the Omnipod 5 system is encouraging. Omnipod 5 is the only FDA-cleared, fully disposable pod-based AID system. The Type 2 indication has significantly expanded the total addressable market for Insulet by making the Omnipod 5 commercially available to more than 5.5 million people in the United States. In line with this, Omnipod 5 maintained strong momentum in new customer starts in the United States and grew sequentially as well as year over year in the second quarter of 2025. This optimism, driven by a solid second-quarter performance and increasing revenues from all reportable business segments, is expected to contribute further.
Insulet’s focus on delivering consumer-focused innovation looks encouraging. In lieu of this, the company recently announced a limited market release of Omnipod Discover in the United States. Omnipod Discover is a digital platform that provides personalized data management, insulin usage insights, and learning materials to optimize patient engagement and outcomes.
Image Source: Zacks Investment Research
In terms of solvency, Insulet exited the second quarter of 2025 with cash and cash equivalents of $1.12 billion and current debt of $461 million. This robust financial stability appears highly promising, especially during the prolonged period of macroeconomic issues. Additionally, the company reported a second-quarter operating profit of $121.1 million, which increased 122.2% year over year, with the operating margin expanding 750 bps. These factors have positively impacted the stock, contributing to its rise.
Factors That May Offset PODD’s Gains
Insulet’s business remains vulnerable to macroeconomic volatility, including the conflict between Russia and Ukraine, supply-chain and logistics disruptions. Further, the implementation of tariffs by the new U.S. government is expected to result in higher product costs during the remainder of 2025. In the second quarter of 2025, selling, general & administrative expenses rose 15.8% year over year.
Also, Insulet operates in a highly competitive environment. Competitive and regulatory conditions in the markets in which Insulet operates constrain its ability to adopt strategies like price increases or other actions that drive up costs.
A Look at PODD’s Estimates
The Zacks Consensus Estimate for 2025 EPS has moved north 6% to $4.59 in the past 30 days.
Stocks to Consider
Some better-ranked stocks in the broader medical space are Envista NVST, Boston Scientific BSX and IDEXX Laboratories IDXX.
Estimates for Envista’s 2025 EPS have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9% yield.
NVST sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Boston Scientific, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.9% against the industry’s -0.8%. BSX shares have rallied 31.3% in the past year. In the last reported quarter, it posted an earnings surprise of 4.2%.
IDEXX, carrying a Zacks Rank #2 at present, has an earnings yield of 2% against the industry’s -4.6%. Shares of the company have jumped 29.1% in the past year against the industry’s 14% decline. In the last reported quarter, it delivered an earnings surprise of 9.7%.
One Big Gain, Every Trading Day
To help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.
Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.
Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Insulet Gains 77.2% in a Year: What's Driving the Rally?

Boston Scientific’s BSX second-quarter 2025 performance was driven by its robust expansion of operations across different geographies outside the United States. The company’s impressive growth within the MedSurg arm provides a favorable opportunity for growth. Meanwhile, headwinds like currency fluctuations and a dull macro scenario pose concern for Boston Scientific’s operations.
Year to date, this Zacks Rank #2 (Buy) company's shares have rallied 18.1% compared with the industry and the S&P 500 composite’s growth of 7.5% and 8.6%, respectively.
The renowned manufacturer of medical devices and products has a market capitalization of $155.90 billion. BSX beat on earnings in each of the trailing four quarters, delivering an average surprise of 8.11%.
Let us delve deeper.
Upsides for BSX Stock
Persistent International Expansion: Within its international regions, Boston Scientific is putting additional efforts to expand its foothold in the emerging markets, which have strong growth potentials based on economic conditions, healthcare sectors and global capabilities. In the second quarter of 2025, despite geopolitical weaknesses, emerging markets registered sturdy revenue growth of 12.1% operationally, year over year.
In Europe, Middle East and Africa (“EMEA”), the company is successfully expanding its base banking on its diverse portfolio, new launches and commercial execution with healthy underlying market demand. In the second quarter, EMEA sales grew 1.8% operationally. In Asia Pacific (“APAC”), it registered strong growth across China, Japan, Australia and New Zealand. Sales in the region grew 15.4% operationally in the second quarter despite ongoing volume-based procurement (VBP) pressures in China.
Impressive MedSurg Market Share Gain: Boston Scientific is consistently gaining market share within its MedSurg segment. The Endoscopy business within MedSurg delivered a strong quarter, growing 8% globally and achieving double-digit growth in the United States. This performance was driven by robust results from anchor products, including EXALT-D, MANTIS, AXIOS, and OverStitch, with notable growth from both ESG and closure procedures. Urology sales grew 28% operationally in the second quarter, driven by the Stone Management and Prosthetic Urology franchises and double-digit growth in Rezum, which received an expanded indication for large glands in the United States during the quarter.
Within Neuromodulation, sales grew 6.6% in the second quarter, with mid-teens growth in the brain franchise, led by continued adoption of Cartesia X/HX leads and Illumina 3D in the United States. The pain franchise grew mid-single digits, led by strong double-digit growth in Intracept.
Downsides for BSX Stock
Exposure to Currency Movement: With Boston Scientific recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations. Unfavorable currency movements have been a major dampener over the past few quarters, as in the case of other important MedTech players. In the second quarter of 2025, the company had 1.2% headwind from foreign exchange on revenues.
Image Source: Zacks Investment Research
Macroeconomic Headwinds Dent Growth: Boston Scientific continues to face a challenging business environment caused by industry-wide macroeconomic pressures, including geopolitical tensions, global supply-chain disruptions and labor market instability. International conflicts and retaliatory trade actions have increased global risks, while volatile financial markets and fluctuating prices for goods and services are squeezing profitability. The company expects the full-year 2025 tariff impact to be approximately $100 million; tariffs still underscore the heightened complexity of the current environment.
BSX Stock’s Estimate Trend
The Zacks Consensus Estimate for 2025 earnings per share has moved north 2.1% to $2.91 in the past 30 days.
The Zacks Consensus Estimate for 2025 revenues is pegged at $19.49 billion, indicating a 16.4% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Envista NVST, Phibro Animal Health PAHC and IDEXX Laboratories IDXX.
Envista has an estimated earnings growth rate of 15.8% for fiscal 2026 compared with the S&P 500 composite’s 11.7% growth. Shares of the company have rallied 15.3% compared with the industry’s 4% growth. NVST’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.5%.
NVST sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 26% compared with the industry’s 14.2%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. PAHC’s shares have surged 63.9% compared with the industry’s 4.1% growth in the past year.
IDEXX, carrying a Zacks Rank #2 at present, has an earnings yield of 2% compared to the industry’s -5%. Shares of the company have rallied 30.1% against the industry’s 15.8% decline. IDXX’s earnings outpaced estimates in each of the trailing four quarters, with the average surprise being 6.1%.
One Big Gain, Every Trading Day
To help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.
Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.
Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Should Boston Scientific Stock Be in Your Portfolio Right Now?

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores?
Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value Score
For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth Score
While good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum Score
Momentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM Score
If you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank
The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.75% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Idexx Laboratories (IDXX)
Headquartered in Westbrook, ME, IDEXX Laboratories, Inc. is a developer, manufacturer and distributor of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
IDXX is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Momentum investors should take note of this Medical stock. IDXX has a Momentum Style Score of A, and shares are up 15.1% over the past four weeks.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2025, while the Zacks Consensus Estimate has increased $0.39 to $12.55 per share. IDXX also boasts an average earnings surprise of +6.1%.
With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, IDXX should be on investors' short list.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock

Teleflex Incorporated TFX recently announced the launch of the Barrigel rectal spacer in Japan, effective immediately following regulatory approval, insurance coverage acceptance and the issuance of appropriate use criteria by Japanese academic societies.
Barrigel’s commercialization in Japan marks a milestone in the company’s global expansion strategy.
TFX Stock’s Likely Trend Following the News
Following the announcement, shares of Teleflex rose 3.7%, closing the session at $124.30. Post Palette's business integration, Palette’s Barrigel continues to gain traction in the United States with strong sequential revenue momentum. Henceforth, we expect the expansion of Barrigel in Japan to maintain the positive market sentiment toward TFX stock.
Teleflex has a market capitalization of $5.55 billion. The company’s earnings yield of 11.3% compares favorably with the industry’s -5.2%. In the trailing four quarters, it delivered an average earnings surprise of 1.9%.
Barrigel rectal spacer is the first and only hyaluronic rectal spacer that separates the prostate from the rectum to protect the latter during radiation therapy treatment for prostate cancer. It is made from Non-Animal Stabilized Hyaluronic Acid. Barrigel rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy. Barrigel rectal spacer is indicated for prostate cancer patients with T1-T3b disease.
Barrigel rectal spacer does not impose time constraints during injection and offers excellent visibility under ultrasound. This allows physicians to monitor the injection in real time and place the required amount precisely. As a result, a reliable distance between the prostate and rectum can be maintained, enabling a safer and more robust radiation therapy planning. This represents a new standard in rectal protection during radiation therapy.
Clinically Proven Efficacy of Barrigel Rectal Spacer
A U.S. clinical study found that 98% of men who were treated with Barrigel rectal spacer met the primary endpoint of achieving at least a 25% reduction in radiation to the rectum. Patients who met the primary endpoint averaged an 85% reduction in rectal V54 Gy radiation to the rectum. Barrigel rectal spacer is also proven superior in the reduction of acute and long-term Grade 1+ GI toxicity at 3 and 6 months compared to control.
Image Source: Zacks Investment Research
Industry Prospects Favoring TFX
Per a Grand View Research report, Japan’s prostate cancer diagnostics market generated revenues of $345.5 million in 2023 and is expected to reach $438.0 million by 2030, exhibiting a CAGR of 3.4% from 2024 to 2030. In 2022, prostate cancer was the most common cancer among men in Japan, with 104.3 million new cases. It accounted for 18% of all cancer diagnoses nationwide.
More Updates From Teleflex
Last month, Teleflex completed its previously announced acquisition of the majority of BIOTRONIK SE & Co. KG’s Vascular Intervention business. Teleflex paid €760 million in cash, minus certain adjustments, including some non-transferring working capital and other customary terms. The acquisition significantly expands the company’s interventional access product line with a wide range of therapeutic offerings, driving an enhanced global presence in the cath lab.
TFX Stock Price Performance
In the past three months, TFX shares have risen 3.9% compared with the industry’s 3.6% growth.
TFX’s Zacks Rank and Other Key Picks
Some other top-ranked stocks in the broader medical space are Envista NVST, Boston Scientific BSX and IDEXX Laboratories IDXX. While Envista sports a Zacks Rank #1 (Strong Buy), Boston Scientific and IDEXX Laboratories carry a Zacks Rank #2 each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Boston Scientific’s shares have rallied 31.3% in the past year. Estimates for the company’s 2025 earnings per share have increased 2.4% to $2.98 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.1%. In the last reported quarter, it posted an earnings surprise of 4.2%.
Estimates for IDEXX Laboratories’ 2025 earnings per share have climbed 3.1% to $12.55 in the past 30 days. Shares of the company have jumped 29.1% in the past year against the industry’s 14% decline. IDEXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%. In the last reported quarter, it delivered an earnings surprise of 9.7%.
See our %%CTA_TEXT%% report – free today!
7 Best Stocks for the Next 30 Days
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Teleflex Stock Gains Following Barrigel's Launch in Japan

Phibro Animal Health PAHC shares climbed 76.4% in a year, showcasing impressive momentum. The stock has outpaced the industry’s 4.9% growth and the S&P 500 Composite’s 16% gain.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.
New Jersey-based Phibro offers a broad range of products for food animals, including poultry, swine, beef, dairy cattle and aquaculture. In addition to animal health and mineral nutrition products, the company manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Phibro’s business is currently concentrated in the livestock sector, and it is investing resources to develop products for the companion animal sector.
Key Factors Behind PAHC’s Surge
Phibro's share price is trending upward, prompted by strong sales recovery within the Mineral Nutrition and Performance Product arms. In line with this, the Mineral Nutrition business grew 4% year over year during the fiscal third quarter. Meanwhile, sales of Performance Products during the quarter also increased 28% year over year, owing to the rising demand for personal care product ingredients. Also, the expanding Animal Health product portfolio, post the recent acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc., is encouraging.
Investors expressed optimism about Phibro’s global footprint that extends to key high-growth regions, including Brazil and other countries in South America, China, India and Southeast Asia, among others. During the fiscal third quarter, the company’s operations in countries outside the United States contributed approximately 40% to its total revenues.
In terms of solvency, the company is in a good position. This is evident from its low short-term-payable debt of $16 million on its balance sheet, which is much less than the total cash and short-term investments of $70.4 million. Additionally, Phibro reported a fiscal third-quarter operating profit of $33.4 million, which increased 67.8% year over year, with the operating margin expanding 204 bps. These factors have positively impacted the stock, contributing to its rise.
Image Source: Zacks Investment Research
Concerns for PAHC
Phibro’s business remains vulnerable to macroeconomic volatility, including the conflict between Russia and Ukraine, supply-chain and logistics disruptions, and heightened cybersecurity threats. The strengthening of the U.S. dollar is currently affecting the company’s export market.
A Glance at PAHC’s Consensus Estimates
Phibro’s fiscal 2025 and 2026 earnings per share (EPS) are expected to increase 71.4% and 12.7% to $2.04 and $2.30, respectively, year over year. In the past 30 days, the Zacks Consensus Estimate for the company's fiscal 2025 EPS has remained unchanged at $2.04.
Revenues for fiscal 2025 are projected to grow 25.7% to $1.28 billion, while the same for fiscal 2026 is expected to reach $1.41 billion, implying a 10.1% increase.
Other Top MedTech Stocks
Some other top-ranked stocks in the broader medical space are Envista NVST, Boston Scientific BSX and IDEXX Laboratories IDXX.
Estimates for Envista’s 2025 EPS have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared with the industry’s 5.2% growth. Its earnings yield of 5.4% has also outpaced the industry’s -0.9% yield.
NVST sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Boston Scientific, currently carrying a Zacks Rank #2, has an earnings yield of 2.9% against the industry’s -0.8%. BSX shares have rallied 31.3% in the past year. In the last reported quarter, it posted an earnings surprise of 4.2%.
IDEXX, carrying a Zacks Rank #2 at present, has an earnings yield of 2% against the industry’s -4.6%. Shares of the company have jumped 29.1% in the past year against the industry’s 14% decline. In the last reported quarter, it delivered an earnings surprise of 9.7%.
#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

PAHC Stock Up 76.4% in a Year: What's Driving the Rally?

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF (Symbol: GSLC) where we have detected an approximate $428.9 million dollar outflow -- that's a 2.9% decrease week over week (from 116,500,000 to 113,100,000). Among the largest underlying components of GSLC, in trading today Alphabet Inc (Symbol: GOOG) is off about 1.1%, Idexx Laboratories, Inc. (Symbol: IDXX) is up about 0.5%, and Fastenal Co. (Symbol: FAST) is higher by about 0.7%. For a complete list of holdings, visit the GSLC Holdings page » The chart below shows the one year price performance of GSLC, versus its 200 day moving average:
Looking at the chart above, GSLC's low point in its 52 week range is $94.8763 per share, with $126.74 as the 52 week high point — that compares with a last trade of $126.27. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
NCS Historical Stock Prices
PCRX Insider Buying
Top Ten Hedge Funds Holding AVXS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

GSLC, GOOG, IDXX, FAST: ETF Outflow Alert

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in diagnosing Alzheimer's disease. Developed by Fujirebio Diagnostics, Inc., the test helps through early detection of the amyloid plaques associated with the disease in appropriate patients.
The latest test builds on and replaces a similar pTau-217/Beta Amyloid 42 Ratio test that Labcorp introduced in April 2025.
Likely Trend of LH Stock Following the News
Following the announcement yesterday, Labcorp shares edged up 0.04%, finishing at $270.49. The path to an Alzheimer's diagnosis has generally involved years of invasive procedures and expensive imaging, prompting the need for faster diagnosis of patients, enrolling in clinical trials, or starting therapies. By offering this FDA-cleared blood test across the nation, the company is playing a key role in delivering innovative solutions for Alzheimer's disease and other neurological conditions by helping patients, families and physicians get answers sooner. We expect the market sentiment toward LH stock to remain positive surrounding this news.
Labcorp has a market capitalization of $22.47 billion. Going by the Zacks Consensus Estimate, the company’s earnings are expected to grow 11.9% in 2025, over a 7.7% increase in revenues. In the trailing four quarters, it delivered an average earnings beat of 2.5%.
More on Labcorp’s New Offering
The Lumipulse pTau-217/Beta Amyloid 42 Ratio offers results comparable to current methods for diagnosis of Alzheimer's disease — cerebrospinal fluid (CSF) testing obtained through lumbar puncture and positron emission tomography (PET) scans — but from a simple blood draw, making it more affordable, more accessible and less invasive. In clinical studies, Fujirebio reported that the test demonstrated a positive predictive value of 92% and a negative predictive value of 97%.
The launch of this test closely follows the release of a new clinical guideline from the Alzheimer's Association, which supports the use of blood-based biomarkers to help evaluate patients suspected of Alzheimer's disease in specialty care settings. The guideline reflects the growing clinical consensus around these tools and underscores the need for expanding access.
Image Source: Zacks Investment Research
The Lumipulse pTau-217/Beta Amyloid 42 Ratio is designed for adults aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. It is not a screening or stand-alone diagnostic test and ought to be interpreted in conjunction with other clinical information of the patient. Once ordered, patients can complete the blood draw in a healthcare provider's office or any of Labcorp's more than 2,200 Patient Service Centers nationwide.
Industry Prospects Back LH
Per a research report, the global Alzheimer’s disease diagnostics market was valued at $8.33 billion in 2024 and is likely to witness a compound annual growth rate of 11% through 2030. Some of the key factors fueling the market’s growth are the increasing prevalence of Alzheimer’s disease, growing adoption of personalized products and increasing technological advancements in medical imaging.
Other Developments at Labcorp
Last month, Labcorp launched Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services. Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations, enhancing the user experience and freeing up more time for patient care.
LH Stock Price Performance
Over the past year, Labcorp shares have rallied 19.8% compared with the industry’s 18.3% rise.
LH’s Zacks Rank and Top MedTech Stocks
Labcorp currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Envista NVST, Boston Scientific BSX and IDEXX Laboratories IDXX. While Envista sports a Zacks Rank #1 (Strong Buy), Boston Scientific and IDEXX Laboratories each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2025 earnings per share have increased 7.6% in the past 30 days. Shares of the company have rallied 16.7% in the past year compared to the industry’s 5.2% rise. Its earnings yield of 5.4% also outpaced the industry’s -0.9% yield. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
Boston Scientific shares have rallied 31.3% in the past year. Estimates for the company’s 2025 earnings per share have increased 2.4% to $2.98 in the past 30 days. BSX’s earnings beat estimates in each of the trailing four quarters, the average surprise being 8.1%. In the last reported quarter, it posted an earnings surprise of 4.2%.
Estimates for IDEXX Laboratories’ 2025 earnings per share have climbed 3.1% to $12.55 in the past 30 days. Shares of the company have jumped 29.1% in the past year against the industry’s 14% fall. IDEXX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.1%. In the last reported quarter, it delivered an earnings surprise of 9.7%.
See our %%CTA_TEXT%% report – free today!
7 Best Stocks for the Next 30 Days
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	48.51 23.75
Price/Sales	11.07 3.01
P/B	29.27 2.20
P/FCF	51.26 18.30

Indicator	TTM Median
ROE	57.36 25.41
ROA	26.97 6.00
ROI	43.71 9.66
Net Worth	43.00 0.20
Quick Ratio	0.81 1.71
Current Ratio	1.16 2.83

Indicator	TTM Median
Net Profit Margin	22.76 10.25
Operating Margin	29.17 14.24
Gross Margin	61.27 68.59
Return on tangible equity	85.81 53.53

Indicator	TTM Median
EPS	2.62 0.37
EPS Forecast	2.40 0.37
Revenue	998.00M 16.00M
Gross Profit	623.00M —
EBITDA	351.00M —

IDEXX Laboratories, Inc.

Fundamental IDXX

Valuation

Debts

Efficiency

Other ratios

Revenue